Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully priced its upsized initial public offering (IPO) of 10,740,000 American depositary shares (ADSs) at $15.00 per ADS, anticipating gross proceeds of approximately $161.1 million. The offering includes a 30-day option for underwriters to purchase an additional 1,611,000 ADSs. Trading on the Nasdaq Global Market is set to begin on February 3, 2023, with completion expected by February 7, 2023. Structure Therapeutics focuses on developing novel oral therapeutics for metabolic and pulmonary diseases, leveraging a structure-based drug discovery platform.